Metabolic
A multi-receptor agonist peptide studied in preclinical metabolic research models.
GLP-3 (RT) is a frequent subject of receptor-pharmacology research: a single peptide that engages three class B GPCRs — the GIP, GLP-1, and glucagon receptors — at once. It appears in in-vitro and animal-model studies of multi-receptor signaling.
Type
Synthetic peptide (acylated, 39 residues)
Molecular formula
C221H342N46O68
Molecular weight
~4,731 g/mol
CAS number
2381089-83-2
Amino acids
39
Fatty acid chain
C20 diacid
Modification
Aib and a-methyl-Leu substitutions; C-terminal amide; Lys-linked C20 fatty-diacid acylation via a gamma-Glu / AEEA linker.
A single-peptide triple agonist built on a GIP backbone that engages three class B GPCRs - the GIP receptor (GIPR), the GLP-1 receptor (GLP-1R) and the glucagon receptor (GCGR). Non-coded residues confer protease resistance; the fatty-diacid side chain confers reversible albumin binding.
Research Focus
Studied in vitro and in preclinical models in receptor pharmacology and metabolic research.
Lyophilized
-20°C (-80°C long term)
powder typically stable ~24 months.
Reconstituted
-20°C ~1 month
2-8°C for short-term working use only.
Aliquot to avoid freeze-thaw; protect from light; keep sealed and dry.
Reviews
Misra S, et al. (2025). J Basic Clin Physiol Pharmacol — Systematic review of GLP-3 (RT) clinical trials in obesity
Systematic review & meta-analysis (2025). PubMed — Systematic review and meta-analysis of GLP-3 (RT) in obesity
Pasqualotto E, et al. (2024). Metabolism Open — Systematic review and meta-analysis of GLP-3 (RT)
Doggrell SA. (2023). Expert Opin Investig Drugs — Review of GLP-3 (RT) pharmacology and development
Clinical
Coskun T, et al. (2025). Lancet Diabetes & Endocrinology — Phase 2 substudy of GLP-3 (RT) and body composition in type 2 diabetes
Giblin K, et al. (2025). Diabetes, Obesity and Metabolism — Design and rationale of the GLP-3 (RT) Phase 3 registrational program
Sanyal AJ, et al. (2024). Nature Medicine — Phase 2a randomized trial of GLP-3 (RT) and hepatic fat in MASLD
Urva S, et al. (2023). Diabetes, Obesity and Metabolism — Study of GLP-3 (RT) and gastric emptying
Jastreboff AM, et al. (2023). NEJM — Phase 2 randomized, placebo-controlled trial of GLP-3 (RT) in adults with obesity
Rosenstock J, et al. (2023). The Lancet — Phase 2 randomized, placebo- and active-controlled trial of GLP-3 (RT) in type 2 diabetes
Urva S, et al. (2022). The Lancet — Phase 1b multiple-cohort study of GLP-3 (RT) in type 2 diabetes
Primary research
Briand F, et al. (2025). Obesity — Preclinical metabolic study of GLP-3 (RT) in diet-induced obese MASH rodent models
Marathe SJ, et al. (2025). npj Metabolic Health and Disease — Preclinical study of GLP-3 (RT) in obesity-associated cancer mouse models
Li W, et al. (2024). Cell Discovery — Cryo-EM structural study of GLP-3 (RT) bound to GLP-1R, GIPR, and GCGR
Regmi A, Roell W. (2023). STAR Protocols — In vitro adipocyte lipolysis protocol with GLP-3 (RT)
Coskun T, et al. (2022). Cell Metabolism — Discovery and translational characterization of GLP-3 (RT) as a triple receptor agonist
Research Use Only
These products are intended for research purposes only and are not for human consumption. Not FDA approved. Not intended to diagnose, treat, cure, or prevent any disease.
